Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Ravinder Jain has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199221-02-2013
21-02-2013
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Ravinder Jain has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 201121-02-2013
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
Ravinder Jain has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 201113-02-2013
Financial Results & Limited Review for Dec 31, 2012
Panacea Biotec Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended December 31, 2012.08-02-2013
Clarifies on news item
With reference to the news item appearing in a leading financial daily titled "Panacca, Bestech Team up to Develop Township ", Panacea Biotec Ltd has clarified to BSE that the Companys Wholly-owned Subsidiary, Best On Health Ltd. (BOH) has signed a Term Sheet with Bestech expiring on February 28, 2013. The definitive agreement has yet not been reached. The Company is evaluating all its options, models and partners. The final call is yet to be taken.06-02-2013
Panacea Biotec Gets Government of India's Order for Supply of Oral Polio Vaccine worth Rs. 187 Crore
Panacea Biotec Ltd has informed BSE regarding a Press Release dated December 17, 2012 titled "Panacea Biotec Gets Government of India's Order for Supply of Oral Polio Vaccine worth Rs. 187 Crore"17-12-2012
Panacea Biotec announces strategic alliance with Kremers Urban for 11 High Barrier to Entry Generics; and the launch of Tacrolimus Capsules in US
Panacea Biotec Ltd has informed BSE regarding "Panacea Biotec announces strategic alliance with Kremers Urban for 11 High Barrier to Entry Generics; and the launch of Tacrolimus Capsules in US".Press Release:"Panacea Biotec, India's highly progressive research based health management Company has entered into a strategic alliance with Kremers Urban Inc. (part of UCB Group) for 11 high barrier to entry generics, whose market size in...19-11-2012
Financial Results & Limited Review for Sep 30, 2012
Panacea Biotec Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended September 30, 2012.09-11-2012
Credit Rating
Panacea Biotec Ltd has informed BSE that Credit Analysis & Research Ltd. (CARE) has revised credit rating pertaining to Long Term Bank Facilities to 'CARE B' (Single B) from 'CARE BB (Double B) and to CARE A4 (A Four) from CARE A4 (A Four) (under credit watch) in regard to Short Term Bank Facilities.'CARE B' (Single B) rating is applicable to instruments having tenure of more than one year and are considered to have high risk of default...31-10-2012
Outcome of AGM
Panacea Biotec Ltd has informed BSE that the 28th Annual General Meeting (AGM) of the Company was held on September 29, 2012. (For more details kindly refer Corporate Announcements on www.bseindia.com).04-10-2012